GlobeNewswire·Oct 26, 2026, 9:05 AM ET

SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

UC Davis has been activated as a clinical trial site for the CERTAIN-T Phase 1 study evaluating CER-1236 in patients with hematologic malignancies.
UC Davis serves as the primary manufacturing site for CER-1236, with activation expected to expand patient recruitment capacity & streamline treatment logistics.
SRX Global Inc. previously announced a definitive agreement to acquire CERo Therapeutics, an operating subsidiary of CERo Therapeutics Holdings, Inc.
Previous data from six patients in the CERTAIN-T study showed no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, dose-limiting toxicities, or treatment-related severe adverse events.
Clinical improvements were observed in two patients, including one with refractory acute myeloid leukemia who underwent allogeneic stem cell transplantation 71 days after infusion.
The CERTAIN-T study initially focused on acute myeloid leukemia & has since expanded to include myelodysplastic syndromes & myelofibrosis.
The proposed acquisition of CERo Therapeutics by SRX Global, announced on October 7, 2026, remains subject to customary closing conditions.